Peer AI has secured $12.1 million in funding to enhance drug approval workflows using its advanced agentic AI platform. The investment round was led by Flare Capital Partners and SignalFire, with contributions from Greycroft, Atria, Alumni Ventures, Gaingels, and Mana Ventures.
The funding will help Peer AI address the regulatory documentation challenges faced by the pharmaceutical industry. Each new drug requires over 200,000 pages of documentation, including clinical study reports and IND applications. The process often faces inefficiencies due to fragmented data and manual workflows, which cause costly delays.
Nearly one-third of FDA submissions encounter quality issues, resulting in approval delays of over 400 days. Peer AI’s platform utilizes AI agents tailored to specific regulatory tasks, significantly improving both speed and accuracy. This domain-specific AI, integrated with human oversight, ensures better compliance and faster documentation processes.
Peer AI’s technology has already helped pharmaceutical companies improve efficiency dramatically. Some clients have reduced the drafting time of clinical study reports from 40 days to just 17, and protocol turnaround times have dropped from weeks to just one week. Documentation speed across early adopters has improved by as much as 94%, reflecting the platform’s growing success.
The platform’s modular architecture includes specialized agents for tasks like content generation, data extraction, formatting, and validation. This enables faster document creation with fewer errors and greater compliance. Peer AI’s approach blends AI precision with the expertise of human medical writers.
With the new funding, Peer AI plans to expand its product development and increase market adoption, tapping into the $15 billion regulatory documentation sector. The company’s leadership team brings years of expertise in AI and life sciences, positioning Peer AI as a leader in transforming regulatory workflows.
Peer AI’s advisory board includes Ariel Katz, CEO of H1, and Brian Longo, a former Veeva Systems executive. The company’s deep domain expertise in both AI and life sciences sets it apart in driving the future of drug approval.